Monitoring the COVID-19 immune landscape in Japan

被引:5
作者
Sasanami, Misaki [1 ]
Kayano, Taishi [1 ]
Nishiura, Hiroshi [1 ]
机构
[1] Kyoto Univ Sch Publ Hlth, Yoshida Konoe,Sakyo, Kyoto 6068601, Japan
基金
日本科学技术振兴机构; 日本学术振兴会;
关键词
COVID-19; Vaccination; Epidemiology; Mathematical model; Statistical model; BNT162B2; VACCINE; HOSPITALIZATIONS; INFECTION; WORKERS;
D O I
10.1016/j.ijid.2022.06.005
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: COVID-19 vaccination in Japan started on February 17, 2021. Because the timing of vaccination and the risk of severe COVID-19 greatly varied with age, the present study aimed to monitor the age-specific fractions of the population who were immune to SARS-CoV-2 infection after vaccination. Methods: Natural infection remained extremely rare, accounting for less than 5% of the population by the end of 2021; thus, we ignored natural infection-induced immunity and focused on vaccine-induced immunity. We estimated the fraction of the population immune to infection by age group using vaccina-tion registry data from February 17, 2021, to October 17, 2021. We accounted for two important sources of delay: (i) reporting delay and (ii) time from vaccination until immune protection develops. Results: At the end of the observation period, the proportion of individuals still susceptible to SARS-CoV-2 infection substantially varied by age and was estimated to be >90% among people aged 0-14 years, in contrast to approximately 20% among the population aged >65 years. We also estimated the effective reproduction number over time using a next-generation matrix while accounting for differences in the proportion immune to infection by age. Conclusion: The COVID-19 immune landscape greatly varied by age, and a substantial proportion of young adults remained susceptible. Vaccination contributed to a marked decrease in the reproduction number.(c) 2022 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
引用
收藏
页码:300 / 306
页数:7
相关论文
共 42 条
[1]   Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021 [J].
Abu Jabal, Kamal ;
Ben-Amram, Hila ;
Beiruti, Karine ;
Batheesh, Yunis ;
Sussan, Christian ;
Zarka, Salman ;
Edelstein, Michael .
EUROSURVEILLANCE, 2021, 26 (06)
[2]  
Andrews N, 2022, NEW ENGL J MED, V386, P1532, DOI [10.1056/NEJMoa2119451, 10.1016/S1473-3099(22)00309-7]
[3]   Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine [J].
Baden, Lindsey R. ;
El Sahly, Hana M. ;
Essink, Brandon ;
Kotloff, Karen ;
Frey, Sharon ;
Novak, Rick ;
Diemert, David ;
Spector, Stephen A. ;
Rouphael, Nadine ;
Creech, C. Buddy ;
McGettigan, John ;
Khetan, Shishir ;
Segall, Nathan ;
Solis, Joel ;
Brosz, Adam ;
Fierro, Carlos ;
Schwartz, Howard ;
Neuzil, Kathleen ;
Corey, Larry ;
Gilbert, Peter ;
Janes, Holly ;
Follmann, Dean ;
Marovich, Mary ;
Mascola, John ;
Polakowski, Laura ;
Ledgerwood, Julie ;
Graham, Barney S. ;
Bennett, Hamilton ;
Pajon, Rolando ;
Knightly, Conor ;
Leav, Brett ;
Deng, Weiping ;
Zhou, Honghong ;
Han, Shu ;
Ivarsson, Melanie ;
Miller, Jacqueline ;
Zaks, Tal .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) :403-416
[4]   SARS-CoV-2 spread and hospitalisations in paediatric patients during the omicron surge [J].
Belay, Ermias D. ;
Godfred-Cato, Shana .
LANCET CHILD & ADOLESCENT HEALTH, 2022, 6 (05) :280-281
[5]   SEROPREVALENCE OF ANTI-SARS-CoV-2 ANTIBODIES IN THE NORTHERN ITALY POPULATION BEFORE THE COVID-19 SECOND WAVE [J].
Berselli, Nausicaa ;
Filippini, Tommaso ;
Paduano, Stefania ;
Malavolti, Marcella ;
Modenese, Alberto ;
Gobba, Fabriziomaria ;
Borella, Paola ;
Marchesi, Isabella ;
Vivoli, Roberto ;
Perlini, Paola ;
Bellucci, Rossana ;
Bargellini, Annalisa ;
Vinceti, Marco .
INTERNATIONAL JOURNAL OF OCCUPATIONAL MEDICINE AND ENVIRONMENTAL HEALTH, 2022, 35 (01) :63-74
[6]  
Bisceglia L, 2022, VACCINES-BASEL, V10, P1
[7]   mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar [J].
Chemaitelly, Hiam ;
Yassine, Hadi M. ;
Benslimane, Fatiha M. ;
Al Khatib, Hebah A. ;
Tang, Patrick ;
Hasan, Mohammad R. ;
Malek, Joel A. ;
Coyle, Peter ;
Ayoub, Houssein H. ;
Al Kanaani, Zaina ;
Al Kuwari, Einas ;
Jeremijenko, Andrew ;
Kaleeckal, Anvar Hassan ;
Latif, Ali Nizar ;
Shaik, Riyazuddin Mohammad ;
Abdul Rahim, Hanan F. ;
Nasrallah, Gheyath K. ;
Al Kuwari, Mohamed Ghaith ;
Al Romaihi, Hamad Eid ;
Al-Thani, Mohamed H. ;
Al Khal, Abdullatif ;
Butt, Adeel A. ;
Bertollini, Roberto ;
Abu-Raddad, Laith J. .
NATURE MEDICINE, 2021, 27 (09) :1614-+
[8]   Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study [J].
Chung, Hannah ;
He, Siyi ;
Nasreen, Sharifa ;
Sundaram, Maria E. ;
Buchan, Sarah A. ;
Wilson, Sarah E. ;
Chen, Branson ;
Calzavara, Andrew ;
Fell, Deshayne B. ;
Austin, Peter C. ;
Wilson, Kumanan ;
Schwartz, Kevin L. ;
Brown, Kevin A. ;
Gubbay, Jonathan B. ;
Basta, Nicole E. ;
Mahmud, Salaheddin M. ;
Righolt, Christiaan H. ;
Svenson, Lawrence W. ;
MacDonald, Shannon E. ;
Janjua, Naveed Z. ;
Tadrous, Mina ;
Kwong, Jeffrey C. .
BMJ-BRITISH MEDICAL JOURNAL, 2021, 374
[9]   BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting [J].
Dagan, Noa ;
Barda, Noam ;
Kepten, Eldad ;
Miron, Oren ;
Perchik, Shay ;
Katz, Mark A. ;
Hernan, Miguel A. ;
Lipsitch, Marc ;
Reis, Ben ;
Balicer, Ran D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (15) :1412-1423
[10]   Data, disease and diplomacy: GISAID's innovative contribution to global health [J].
Elbe, Stefan ;
Buckland-Merrett, Gemma .
GLOBAL CHALLENGES, 2017, 1 (01) :33-46